Sentences with phrase «price growth over»

So the home price growth over that time period would be the equity that the home buyer would have accumulated.»

The expansive cities also experienced real housing price growth over the period — just not as much as the expensive ones.

In a report released last week, Moody's Analytics assured that while the Canadian real estate sector will experience a more relaxed pace in home price growth over the next half decade, rumors of a massive crash are greatly exaggerated.

Many California cities experienced tremendous price growth over the last few years.

Smaller homes have seen significant price growth over larger ones, and that means some homeowners may be sitting on a lot of equity, more than they may realize.

the price growth over the last year is astonishing with North Vancouver and New Westminster leading.

According to FNB's figures, the Western Cape has seen exceptional house price growth over the past five years of 50.4 % to the end of December 2017, with KwaZulu - Natal trailing behind at 31.9 %.

This in turn will drive increased property price growth over time.

Agricultural land in the Great Plains has seen strong price growth over the past few years, as institutional investors found it an attractive hedge instrument against inflation expectations, coupled with strong returns.

Additionally, the company's forecasts suggest that first - time home buyers in these cities will see strong price growth over the next year, allowing them to accumulate equity.

Some Bay Area housing market forecasts for 2017 are predicting a slowdown in price growth over the coming months.

Additionally, the company's forecasts suggest that first - time home buyers in these cities will see strong price growth over the next year, allowing them to accumulate equity.

We expect these two markets to post the fastest home price growth over the next few years,» concludes Ms Petramala.

To put this in perspective, «average» home price growth over the last few decades is somewhere between 3 % and 5 %.

Still, he expects good share - price growth over the next few years, and if Europe's economic fortunes improve, then investors could see stocks soar.

Not exact matches

Important factors that could cause actual results to differ materially from those reflected in such forward - looking statements and that should be considered in evaluating our outlook include, but are not limited to, the following: 1) our ability to continue to grow our business and execute our growth strategy, including the timing, execution, and profitability of new and maturing programs; 2) our ability to perform our obligations under our new and maturing commercial, business aircraft, and military development programs, and the related recurring production; 3) our ability to accurately estimate and manage performance, cost, and revenue under our contracts, including our ability to achieve certain cost reductions with respect to the B787 program; 4) margin pressures and the potential for additional forward losses on new and maturing programs; 5) our ability to accommodate, and the cost of accommodating, announced increases in the build rates of certain aircraft; 6) the effect on aircraft demand and build rates of changing customer preferences for business aircraft, including the effect of global economic conditions on the business aircraft market and expanding conflicts or political unrest in the Middle East or Asia; 7) customer cancellations or deferrals as a result of global economic uncertainty or otherwise; 8) the effect of economic conditions in the industries and markets in which we operate in the U.S. and globally and any changes therein, including fluctuations in foreign currency exchange rates; 9) the success and timely execution of key milestones such as the receipt of necessary regulatory approvals, including our ability to obtain in a timely fashion any required regulatory or other third party approvals for the consummation of our announced acquisition of Asco, and customer adherence to their announced schedules; 10) our ability to successfully negotiate, or re-negotiate, future pricing under our supply agreements with Boeing and our other customers; 11) our ability to enter into profitable supply arrangements with additional customers; 12) the ability of all parties to satisfy their performance requirements under existing supply contracts with our two major customers, Boeing and Airbus, and other customers, and the risk of nonpayment by such customers; 13) any adverse impact on Boeing's and Airbus» production of aircraft resulting from cancellations, deferrals, or reduced orders by their customers or from labor disputes, domestic or international hostilities, or acts of terrorism; 14) any adverse impact on the demand for air travel or our operations from the outbreak of diseases or epidemic or pandemic outbreaks; 15) our ability to avoid or recover from cyber-based or other security attacks, information technology failures, or other disruptions; 16) returns on pension plan assets and the impact of future discount rate changes on pension obligations; 17) our ability to borrow additional funds or refinance debt, including our ability to obtain the debt to finance the purchase price for our announced acquisition of Asco on favorable terms or at all; 18) competition from commercial aerospace original equipment manufacturers and other aerostructures suppliers; 19) the effect of governmental laws, such as U.S. export control laws and U.S. and foreign anti-bribery laws such as the Foreign Corrupt Practices Act and the United Kingdom Bribery Act, and environmental laws and agency regulations, both in the U.S. and abroad; 20) the effect of changes in tax law, such as the effect of The Tax Cuts and Jobs Act (the «TCJA») that was enacted on December 22, 2017, and changes to the interpretations of or guidance related thereto, and the Company's ability to accurately calculate and estimate the effect of such changes; 21) any reduction in our credit ratings; 22) our dependence on our suppliers, as well as the cost and availability of raw materials and purchased components; 23) our ability to recruit and retain a critical mass of highly - skilled employees and our relationships with the unions representing many of our employees; 24) spending by the U.S. and other governments on defense; 25) the possibility that our cash flows and our credit facility may not be adequate for our additional capital needs or for payment of interest on, and principal of, our indebtedness; 26) our exposure under our revolving credit facility to higher interest payments should interest rates increase substantially; 27) the effectiveness of any interest rate hedging programs; 28) the effectiveness of our internal control over financial reporting; 29) the outcome or impact of ongoing or future litigation, claims, and regulatory actions; 30) exposure to potential product liability and warranty claims; 31) our ability to effectively assess, manage and integrate acquisitions that we pursue, including our ability to successfully integrate the Asco business and generate synergies and other cost savings; 32) our ability to consummate our announced acquisition of Asco in a timely matter while avoiding any unexpected costs, charges, expenses, adverse changes to business relationships and other business disruptions for ourselves and Asco as a result of the acquisition; 33) our ability to continue selling certain receivables through our supplier financing program; 34) the risks of doing business internationally, including fluctuations in foreign current exchange rates, impositions of tariffs or embargoes, compliance with foreign laws, and domestic and foreign government policies; and 35) our ability to complete the proposed accelerated stock repurchase plan, among other things.

Larry Puglia, whose T. Rowe Price Blue Chip Growth Fund has trounced the S&P 500 with annualized returns of 18.5 % over the past five years (and 37 % in 2017 alone), says that some of the same companies he avoided around the turn of the millennium are now among the biggest holdings in his portfolio, including Amazon (amzn), Alphabet (googl), and Microsoft (msft).

BAML also cites corporate earnings growth as a tailwind to stock prices, though it notes that global purchasing manager data is «rolling over,» signaling a slowdown to come.

The differences in opinion arise primarily over valuation and whether its rapid growth can continue to justify a price - to - earnings ratio that rarely falls below 40 and has peaked as high as 138.

«If we assume extremely pessimistic nominal earnings growth of 3 % over the coming decade and a compression in the price - earnings ratio to 10, equities would still deliver returns above current bond yields.

When you purchase a broad swath of equities, say an S&P 500 index fund, the returns you can expect over the next decade or so comprise four building blocks: the starting dividend yield, projected growth in real earnings per share, expected inflation, and the expected change in «valuation» — that is, the expansion or contraction in the price / earnings (P / E) multiple.

The growth of solar power over the next decade could cut the price of energy in WA, according to a man involved in one of the latest projects to take a step forward.

According to Panera, the growth in the MyPanera program has allowed the company to significantly increase the efficiency of its marketing, and perhaps not coincidentally, over the past year, the company's stock price has increased almost 30 percent.

«Faster economic growth over most of the past year has tightened labor and product markets and helped to boost prices at a faster pace,» David Berson, chief economist at Nationwide, said in a note.

However, improving commodities prices in 2016 will help restore confidence and Canada will get back on track to sustainable growth over the long term.

He points out that the double - digit growth much of the emerging market experienced in 2010 is over, so it's unlikely we'll see oil prices rise, at least in the short term.

While the cryptocurrency industry is still in fledgling stages — Bitcoin, whose price currently hovers just below $ 11,500, was invented just over nine years ago — its explosive growth is already fueling mergers and acquisitions that could lead to greater consolidation.

If Netflix sees high revenue increases over the next couple of years, based on strong subscriber growth, customer retention, and low marketing spend, he predicts the share price could reach $ 480.

CNBC's Jackie DeAngelis reports on the trading action in crude, as oil prices slide on global growth worries over demand.

Because PE is a measure of earnings over time, you can think of it as representing the number of years required to pay back a stock's purchase price (ignoring inflation, earnings growth and the time value of money).

T - Mobile accounted for nearly all of the subscriber growth in wireless over the past few years, and the other carriers are cutting prices and adding promotional offers to catch up.

Canada has posted some of its weakest economic growth outside of a recession over the past couple of years in part because business investment sunk along with the price of oil.

Oil prices have been unusually volatile over the last week, so predicting third quarter economic growth is a bit of a fool's errand when we don't have a good feel on what the rest of the third quarter will bring for oil prices (and what we do know is not good).

Let's say that, over the next two years, the QE taper pushes rates on the most popular 30 - year mortgages up to 5.5 %, from 4.5 % today, and home price growth slows to 5 % year - over-year from the current 12 %.

Fueled by a surge of renters across all age ranges, rental prices nationally have grown at roughly twice the pace of average hourly wage growth, which was a paltry 2.1 percent over the past year.

And the bulk of that growth has been at the upper end of the market: Over the past five years, reports the Distilled Spirits Council, sales of «value» bourbon — priced below $ 15 — have grown just 13 %, while super-premium bourbons, the category that Elmer T. Lee pioneered a generation ago, are up 97.5 %.

The market's price - to - earnings ratio (based on the latest 12 months reported results) raced higher in late 2017 and through January on growth - stock leadership and enthusiasm over tax - cut - juiced profit windfalls for companies.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

The Southeast Asian economy expanded 4.9 percent on - year over the April - June period amid uncertainties in global growth, persistent weakness in oil prices and the spreading of what is being called the country's worst - ever political crisis.

According to a Bain analysis, 45 % of TSR growth at publicly traded global healthcare companies over the past five years came from an expansion of price - to - earnings multiples — that is more than growth from either revenue or earnings.

At the point the growth began to slow, the multiple would contract, meaning that even if its earnings do grow 600 % in the next few years, if it becomes subject to the law of big numbers - that ever increasing amounts eventually forge their own anchor - the result would be a market capitalization substantially similar to today, leading to no increase in the stock price over a long period of time.

The government said last week it will postpone plans to cut the number of permits available and slow traffic growth, responding to the outcry over soaring prices.

But anyone hoping for the kind of stock growth Shoppers enjoyed over the past decade — when its share price climbed from less than $ 18 to, at one point, over $ 55 — will be disappointed.

Right now with earnings growth very strong and the bond market already reflecting a fair amount of Fed tightening (pricing in 5 rate hikes over the coming 2 years), my sense is that the stock market is in OK shape to withstand some tightening of financial conditions and not unravel in the process.

Broadly, we still prefer equities over credit due to strong earnings growth, modestly cheaper valuations following last month's swoon and market's pricing in expectations of Fed rate increases.

The social media company also warned of slowing year - over - year revenue growth due to a drop in ad prices.

According to a recent Morgan Stanley Research report, U.S. commercial real - estate pricing in 2017 could drop by as much as 10 %, year over year, amid slowing revenue growth, rising interest rates and tightening lending conditions.

Chair Yellen, with real growth over the recovery a little slower than we thought, output gaps and job market slack still on the scene, prices appearing to decelerate and wages / compensation revealing little in the way of threatening pressures, try as I might — and I repeat, I'm solidly in your camp — I don't see the rationale for tightening, even a little.

There are a multitude of reasons as to why this occurs but it's a powerful enough force that many investors have done quite well for themselves over an investing lifetime by focusing on dividend stocks, specifically one of two strategies - dividend growth, which focuses on acquiring a diversified portfolio of companies that have raised their dividends at rates considerably above average and high dividend yield, which focuses on stocks that offer significantly above - average dividend yields as measured by the dividend rate compared to the stock market price.

A number of factors have contributed, including concerns about dropping oil prices, slowing growth in China and geopolitical tensions (among them, concerns over the Syrian civil war and refugee crisis and ISIS attacks).